Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.67 |
| ▸ | MEN1 | O00255 | 5/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | TP53 | P04637 | 3/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | RORC | P51449 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29978306 | 1.00 | MAPT (0.68) | MAPTKMT2AMEN1HSD17B10SMN1; SMN2 | |
| SCHEMBL665117 | 0.89 | MAPT (0.75) | MAPTKMT2AMEN1HSD17B10SMN1; SMN2 | |
| SCHEMBL663265 | 0.88 | KMT2A (0.74) | MAPTKMT2AMEN1SMN1; SMN2TP53 | |
| SCHEMBL10186956 | 0.87 | NR3C1 (0.66) | MAPTKMT2AMEN1SMN1; SMN2LMNA | |
| SCHEMBL664662 | 0.86 | RORC (0.64) | MAPTKMT2AMEN1SMN1; SMN2TP53 | |
| SCHEMBL662929 | 0.86 | KMT2A (0.77) | MAPTKMT2AMEN1SMN1; SMN2TP53 | |
| SCHEMBL663814 | 0.85 | MAPT (0.76) | MAPTKMT2AMEN1SMN1; SMN2TP53 | |
| SCHEMBL665609 | 0.85 | MEN1 (0.65) | MAPTKMT2AMEN1SMN1; SMN2TP53 | |
| SCHEMBL663769 | 0.84 | KMT2A (0.59) | MAPTKMT2AMEN1SMN1; SMN2TP53 | |
| SCHEMBL29978377 | 0.84 | KMT2A (0.59) | MAPTKMT2AMEN1SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834446-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834446-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230110928-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | STEMSYNERGY THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-11512081-B2 | Methods and compositions useful in treating cancer and reducing WNT mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2022-11-29 | — | — | US | disclosed |
| US-20210188835-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | STEMSYNERGY THERAPEUTICS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210188835-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | STEMSYNERGY THERAPEUTICS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-10975067-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-10975067-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| EP-3626240-A1 | PROCESS OF PREPARATION OF A N-ARYL BENZYL SULFONAMIDE SUBSTITUTED WITH AN AMIDO GROUP | StemSynergy Therapeutics, Inc. (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3626240-A1 | PROCESS OF PREPARATION OF A N-ARYL BENZYL SULFONAMIDE SUBSTITUTED WITH AN AMIDO GROUP | StemSynergy Therapeutics, Inc. (US) | 2020-03-25 | — | — | EP | disclosed |
| US-20170066755-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | STEMSYNERGY THERAPEUTICS, INC. | 2017-03-09 | — | — | US | disclosed |
| US-9416101-B2 | Methods and compositions useful in treating cancer and reducing WNT mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9416101-B2 | Methods and compositions useful in treating cancer and reducing WNT mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-20150051177-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | STEMSYNERGY THERAPEUTICS, INC. | 2015-02-19 | — | — | US | disclosed |
| US-20150051177-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | STEMSYNERGY THERAPEUTICS, INC. | 2015-02-19 | — | — | US | disclosed |
| US-8901306-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901306-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20120046250-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | STEMSYNERGY THERAPEUTICS, INC (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046250-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | STEMSYNERGY THERAPEUTICS, INC (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2010101964-A2 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | STEMSYNERGY THERAPEUTICS, INC (US) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834446-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | WNT3A, WNT1, WNT3 | MAPT 3825/4885KMT2A 3839/4885MEN1 4226/4885 |
| US-10975067-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | WNT3A, WNT1, WNT3 | MAPT 3825/4885KMT2A 3839/4885MEN1 4226/4885 |
| US-20170066755-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | WNT3A, WNT1, WNT3 | MAPT 3825/4885KMT2A 3839/4885MEN1 4226/4885 |
| US-20230110928-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | WNT3A, WNT1, WNT3 | MAPT 3825/4885KMT2A 3839/4885MEN1 4226/4885 |
| US-20150051177-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | WNT3A, WNT1, WNT3 | MAPT 3825/4885KMT2A 3839/4885MEN1 4226/4885 |
| US-11512081-B2 | Methods and compositions useful in treating cancer and reducing WNT mediated effects in a cell | WNT3A, WNT1, WNT3 | MAPT 3825/4885KMT2A 3839/4885MEN1 4226/4885 |
| US-20120046250-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | WNT3A, WNT1, WNT3 | MAPT 3825/4885KMT2A 3839/4885MEN1 4226/4885 |
| US-20210188835-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | WNT3A, WNT1, WNT3 | MAPT 3825/4885KMT2A 3839/4885MEN1 4226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.